Therapeutic Immunoglobulin Intravenous (IVIg), approved to treat a wide range of autoimmune and primary immunodeficiency diseases, contain mixture of polyreactive and polyclonal IgG purified from the pooled plasma of thousands of donors. The aim of this study is to characterize the profiles of a...
A therapeutic target in RA is CD20, and the anti-CD20 antibody Rituxan® (Rituximab), (a chimeric mouse/human monoclonal antibody developed by IDEC Pharmaceuticals) is used in RA treatment. However, Rituxan® contains DR1 and DR4 restricted T cell epitopes, which in the RA population ...
Pure Protein’s pioneering approach produces soluble forms of HLA Class I and II proteins (sHLA). These molecules support the development of diagnostic and therapeutic applications by creating properly configured and reproducible native HLA proteins in an industrialized and standardized process. This propr...
To the best of our knowledge, this is the first investigation on intra-patient clonal diversity in HLA class I peptide presentation. The findings we distill here should ultimately contribute towards improving therapeutic considerations and efficacy in personalized immunotherapy. ...
Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results. Transpl Immunol. 2015;32. https://doi.org/10.1016/j.trim.2015.04.004. Gebel HM, Bray RA. HLA antibody detection with solid phase assays: Great expectations or expectations too great? Am...
HLA class II was not detectable after culture in chondrogenic media, although a low expression was detected after 48 hours of IFN-γ treatment. After full osteogenic and chondrogenic differentiation, tissues reacted strongly with the mouse anti-HLA class I monoclonal antibody. However, unlike ...
Hyperexpression of classical HLA class I (HLA-I) molecules in insulin-containing islets has become a widely accepted hallmark of type 1 diabetes pathology. In comparison, relatively little is known about the expression, function and role of non-classical subtypes of HLA-I. This review focuses on...
These antigens are presented by MHC class I molecules and are recognized by cytotoxic T cells, which consequently destroy tumor cells. However, tumors develop strategies to escape such immune surveillance. HLA-I loss is believed to be one of the major mechanisms, and it was reported in ...
Interferon (IFN)-α is the earliest cytokine signature observed in individuals at risk for type 1 diabetes (T1D), but the effect of IFN-α on the antigen repertoire of HLA Class I (HLA-I) in pancreatic β-cells is unknown. Here we characterize the HLA-I
Finally, these glomerulocapillary miRNAs could be novel therapeutic targets in ABMR. Methods In vitro model of anti-HLA-class I alloantibody binding Primary human renal glomerular endothelial cells (GECs) were cultivated according to the vendor’s instructions (4000; ScienCell, Carlsbad, CA, USA)...